BioProcess Insider Interview with Enzene CEO Himanshu Gadgil, PhD and Dan Stanton

We haven’t really seen a product that works in fed-batch that does not work in perfusion”, shares our CEO, Himanshu Gadgil. With a 100% success rate in transitioning 30 fed-batch processes to our fully-connected continuous manufacturing platform, we’re excited to bring this cutting-edge technology to our new 54,000 sq. ft. facility in New Jersey. Our mission ❓ To democratize access to life-saving therapies. With further advancements to our technology, we’re rolling out EnzeneX™ 2.0, that integrates real-time analytics for continuous data monitoring and optimization. As we expand, our commitment to delivering innovative solutions that meet the evolving needs of our global clients remains stronger than ever. For deeper insights into Enzene’s advancements, watch our CEO’s interview at the BIO International Conference 2024, where he discusses our latest innovations with Dan Stanton, the Managing editor of BioProcess Insider.